In Brief This Week: Oxford Nanopore; Natera; Inivata; and More | GenomeWeb

NEW YORK (GenomeWeb) – Oxford Nanopore said this week that it has opened the PromethIon Early Access Program (PEAP) to allow researchers to get first access to the technology. The PromethIon is a desktop device for high-throughput, high-sample number, nanopore-based analysis of DNA and RNA. It works the same way as Oxford's MinIon, the company said, but on a larger scale. PEAP participants will receive a PromethIon, installation support, flow cells, and reagent kits, and access to online support communities.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.